Trastuzumab biosimilar (Dr. Reddy's Laboratories)

曲妥珠单抗生物类似药 (Dr. Reddy's Laboratories)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (Dr. Reddy's Laboratories)

Drug Alias Name曲司珠单抗生物仿制药 (Dr. Reddy's Laboratories)Trastuzumab (Dr. Reddy's Laboratories)群司珠单抗生物仿制药 (Dr. Reddy's Laboratories)Trastuzumabum (Dr. Reddy's Laboratories)曲妥珠单抗生物仿制药(Dr. Reddy's Laboratories) +[6]

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsBreast Neoplasms

Approved Indications in ChinaN/A

Original Approved Country/TerritoryIndia

Original Approved Date2018/07/26

Country/TerritoryIndia

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesDr.Reddy's Laboratories Ltd

China Registration ClassN/A

Develop Information

Active CompaniesDr.Reddy's Laboratories Ltd

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeL01XC03